Morgan Stanley maintained Overweight on Dyne Therapeutics, Inc. (DYN) on March 02, 2026. This DYN analyst rating came with a price target lowered to $47, and the firm left the core rating unchanged.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Analyzing the recent 7.9% decline in Custom Truck One Source (CTOS-WT) stock on NYSE, exploring sector trends and technical indicators.
Pre-market update on 1337.HK stock: Razer at HK$2.80 on heavy volume; short-term forecast and Meyka grade
Explore Ripple’s strategic expansion into traditional finance and its potential impact on XRP market value.
Utah’s economic growth is driving business opportunities and investment, marking a 75% increase in business volume.
Explore Yuichiro Tamaki’s influence on Japanese politics and economy, and its implications for investor sentiment.
Ray Dalio Bitcoin allocation gains fresh support as Bitwise stress test shows gold and bitcoin together improve risk-adjusted returns. Clear steps for Swiss investors comparing gold vs bitcoin for CHF